Skip to main content
. Author manuscript; available in PMC: 2019 Sep 1.
Published in final edited form as: Med Res Rev. 2018 May 4;38(6):1974–2023. doi: 10.1002/med.21503

Figure 26.

Figure 26

The substrate-based concepts that were exploited to design active site peptidomimetic inhibitors of FXIa. A) Tetrapeptide design “P4-P2-P1-P1′” as with inhibitor 6 (Ki =30 nM; PDB ID: 1ZOM); B) Tripeptide design “P1-P1′-P2′” as with inhibitor 53 (Ki = 0.3 nM; PDB ID: 4TY7); and C) Tripeptide design “P2-P1-P2′” as with inhibitor 57 (Ki= 0.04 nM; PDB ID: 4Y8Z).